5256 related articles for article (PubMed ID: 15118125)
1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG; Jänne PA; Lee JC; Tracy S; Greulich H; Gabriel S; Herman P; Kaye FJ; Lindeman N; Boggon TJ; Naoki K; Sasaki H; Fujii Y; Eck MJ; Sellers WR; Johnson BE; Meyerson M
Science; 2004 Jun; 304(5676):1497-500. PubMed ID: 15118125
[TBL] [Abstract][Full Text] [Related]
2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
3. Cancer. A bull's eye for targeted lung cancer therapy.
Minna JD; Gazdar AF; Sprang SR; Herz J
Science; 2004 Jun; 304(5676):1458-61. PubMed ID: 15178790
[No Abstract] [Full Text] [Related]
4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
6. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
8. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
[TBL] [Abstract][Full Text] [Related]
11. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Rizvi NA; Rusch V; Pao W; Chaft JE; Ladanyi M; Miller VA; Krug LM; Azzoli CG; Bains M; Downey R; Flores R; Park B; Singh B; Zakowski M; Heelan RT; Shen R; Kris MG
Clin Cancer Res; 2011 May; 17(10):3500-6. PubMed ID: 21558399
[TBL] [Abstract][Full Text] [Related]
13. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Tam IY; Leung EL; Tin VP; Chua DT; Sihoe AD; Cheng LC; Chung LP; Wong MP
Mol Cancer Ther; 2009 Aug; 8(8):2142-51. PubMed ID: 19671738
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
15. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
Taniguchi K; Okami J; Kodama K; Higashiyama M; Kato K
Cancer Sci; 2008 May; 99(5):929-35. PubMed ID: 18325048
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Kimura H; Suminoe M; Kasahara K; Sone T; Araya T; Tamori S; Koizumi F; Nishio K; Miyamoto K; Fujimura M; Nakao S
Br J Cancer; 2007 Sep; 97(6):778-84. PubMed ID: 17848912
[TBL] [Abstract][Full Text] [Related]
18. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Shimizu J; Horio Y; Mitsudomi T
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720
[TBL] [Abstract][Full Text] [Related]
19. Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Saito K; Takigawa N; Ohtani N; Iioka H; Tomita Y; Ueda R; Fukuoka J; Kuwahara K; Ichihara E; Kiura K; Kondo E
Mol Cancer Ther; 2013 Aug; 12(8):1616-28. PubMed ID: 23761220
[TBL] [Abstract][Full Text] [Related]
20. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]